The buzz around novel obesity treatments including Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, shows no sign of quietening down in 2024. Obesity was the most talked about therapy area at the recent 2024 J.P. Morgan Healthcare Conference, with recent M&A activity and a heaping pipeline of new drugs set to enter the space underscoring the size of the market opportunity. Will 2024 bring incremental innovations, increased payer coverage and supply improvements, or will we see more radical changes? Only time will tell. But in the meantime, here’s what ZS experts focused on obesity think is likely to happen.
A7 Satta Result & Chart Updates
Looking for organized market updates and historical records? A7 Satta brings daily result information, multiple market listings, live updates, and monthly chart records together…